Journal of Clinical Oncology, Vol 16, 462-469, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers

S Sjogren, M Inganas, A Lindgren, L Holmberg and J Bergh
Department of Oncology, Akademiska Sjukhuset, Uppsala University, Sweden. sigrid.sjogren@onkologi.uu.se

PURPOSE: To investigate the prognostic and predictive value of c-erbB-2 overexpression in breast cancer in relation to other prognostic markers. PATIENTS AND METHODS: Paraffin-embedded tumors from 315 consecutive primary breast cancer patients were screened for c-erbB-2 protein (p185) overexpression by immunohistochemistry using the monoclonal antibody CB11. RESULTS: c-erbB-2 protein overexpression was detected in 19% of tumors and was associated with shorter 5-year overall survival (OAS) rate compared with c-erbB-2-negative cases in the total patient material (58% and 77%, respectively; P = .004) and in the 96 node-positive patients (31% and 61%, respectively; P = .02), but not in node-negative patients. For 47 node-positive patients treated with adjuvant tamoxifen and radiotherapy, the 5-year OAS was 13% for c- erbB-2 overexpression and 75% for c-erbB-2-negative patients (P = .00004). The frequency of c-erbB-2 overexpression decreased with age at diagnosis. The prognostic value of c-erbB-2 on OAS was independent of age, node status, tumor size, histopathologic grade, hormone receptor status, S phase, p53 status, and adjuvant treatment. c-erbB-2 status added prognostic information to p53-negative and low S-phase cases, but not to p53-positive and high S-phase cases. Correspondingly, these only added information to c-erbB-2-negative cases. CONCLUSION: c-erbB-2 protein overexpression may have a predictive value with regard to adjuvant therapy in node-positive patients, for whom adjuvant tamoxifen with radiotherapy appears insufficient in the presence of c-erbB-2 overexpression. Combination of conventional and newer tumor markers may identify patients with a worse prognosis within groups with a generally favorable prognosis.

This article has been cited by other articles:

				P. J. Whittington, M. P. Piechocki, H. H. Heng, J. B. Jacob, R. F. Jones, J. B. Back, and W.-Z. Wei DNA Vaccination Controls Her-2+ Tumors that Are Refractory to Targeted Therapies Cancer Res., September 15, 2008; 68(18): 7502 - 7511. [Abstract] [Full Text] [PDF]

				S. Makkat, R. Luypaert, T. Stadnik, C. Bourgain, S. Sourbron, M. Dujardin, J. De Greve, and J. De Mey Deconvolution-based Dynamic Contrast-enhanced MR Imaging of Breast Tumors: Correlation of Tumor Blood Flow with Human Epidermal Growth Factor Receptor 2 Status and Clinicopathologic Findings--Preliminary Results Radiology, September 9, 2008; (2008) 2492071147. [Abstract] [Full Text]

				A. Naiki-Ito, M. Asamoto, N. Hokaiwado, S. Takahashi, H. Yamashita, H. Tsuda, K. Ogawa, and T. Shirai Gpx2 Is an Overexpressed Gene in Rat Breast Cancers Induced by Three Different Chemical Carcinogens Cancer Res., December 1, 2007; 67(23): 11353 - 11358. [Abstract] [Full Text] [PDF]

				D. R. Emlet, K. A. Brown, D. L. Kociban, A. A. Pollice, C. A. Smith, B. B. L. Ong, and S. E. Shackney Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines Mol. Cancer Ther., October 1, 2007; 6(10): 2664 - 2674. [Abstract] [Full Text] [PDF]

				L. R. Rodrigues, J. A. Teixeira, F. L. Schmitt, M. Paulsson, and H. Lindmark-Mansson The Role of Osteopontin in Tumor Progression and Metastasis in Breast Cancer Cancer Epidemiol. Biomarkers Prev., June 1, 2007; 16(6): 1087 - 1097. [Abstract] [Full Text] [PDF]

				J Bergqvist, J. Ohd, J Smeds, S Klaar, J Isola, H Nordgren, G. Elmberger, H Hellborg, J Bjohle, A-L Borg, et al. Quantitative real-time PCR analysis and microarray-based RNA expression of HER2 in relation to outcome Ann. Onc., May 1, 2007; 18(5): 845 - 850. [Abstract] [Full Text] [PDF]

				S.-S. Ko, Y.-S. Na, C.-S. Yoon, J.-Y. Park, H.-S. Kim, M.-H. Hur, H.-K. Lee, Y.-K. Chun, S.-S. Kang, B.-W. Park, et al. The Significance of c-erbB-2 Overexpression and p53 Expression in Patients With Axillary Lymph Node--Negative Breast Cancer: A Tissue Microarray Study International Journal of Surgical Pathology, April 1, 2007; 15(2): 98 - 109. [Abstract] [PDF]

				A. Belosay, A. M.H. Brodie, and V. C.O. Njar Effects of Novel Retinoic Acid Metabolism Blocking Agent (VN/14-1) on Letrozole-Insensitive Breast Cancer Cells Cancer Res., December 1, 2006; 66(23): 11485 - 11493. [Abstract] [Full Text] [PDF]

				S-Y Kong, J H Kang, Y Kwon, H-S Kang, K-W Chung, S H Kang, D H Lee, J Ro, and E S Lee Serum HER-2 concentration in patients with primary breast cancer J. Clin. Pathol., April 1, 2006; 59(4): 373 - 736. [Abstract] [Full Text] [PDF]

				H. J. Huang, P. Neven, M. Drijkoningen, R. Paridaens, H. Wildiers, E. Van Limbergen, P. Berteloot, F. Amant, I. Vergote, and M. R. Christiaens Hormone receptors do not predict the HER2/neu status in all age groups of women with an operable breast cancer Ann. Onc., November 1, 2005; 16(11): 1755 - 1761. [Abstract] [Full Text] [PDF]

				R Ainsworth, J M S Bartlett, J J Going, E A Mallon, A Forsyth, J Richmond, W Angerson, A Watters, and B Dunne IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTestTM in breast carcinoma J. Clin. Pathol., October 1, 2005; 58(10): 1086 - 1090. [Abstract] [Full Text] [PDF]

				H J Huang, P Neven, M Drijkoningen, R Paridaens, H Wildiers, E Van Limbergen, P Berteloot, F Amant, I Vergote, and M R Christiaens Association between tumour characteristics and HER-2/neu by immunohistochemistry in 1362 women with primary operable breast cancer J. Clin. Pathol., June 1, 2005; 58(6): 611 - 616. [Abstract] [Full Text] [PDF]

				M. Cianfrocca and L. J. Goldstein Prognostic and Predictive Factors in Early-Stage Breast Cancer Oncologist, November 1, 2004; 9(6): 606 - 616. [Abstract] [Full Text] [PDF]

				J. E. Thompson and C. B. Thompson Putting the Rap on Akt J. Clin. Oncol., October 15, 2004; 22(20): 4217 - 4226. [Abstract] [Full Text] [PDF]

				H. Yaziji, L. C. Goldstein, T. S. Barry, R. Werling, H. Hwang, G. K. Ellis, J. R. Gralow, R. B. Livingston, and A. M. Gown HER-2 Testing in Breast Cancer Using Parallel Tissue-Based Methods JAMA, April 28, 2004; 291(16): 1972 - 1977. [Abstract] [Full Text] [PDF]

				J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398. [Abstract] [Full Text] [PDF]

				T. Lindahl, G. Landberg, J. Ahlgren, H. Nordgren, T. Norberg, S. Klaar, L. Holmberg, and J. Bergh Overexpression of cyclin E protein is associated with specific mutation types in the p53 gene and poor survival in human breast cancer Carcinogenesis, March 1, 2004; 25(3): 375 - 380. [Abstract] [Full Text] [PDF]

				I Guerra, J Algorta, R Diaz de Otazu, A Pelayo, and J Farina Immunohistochemical prognostic index for breast cancer in young women Mol. Pathol., December 1, 2003; 56(6): 323 - 327. [Abstract] [Full Text] [PDF]

				J. S. Ross, J. A. Fletcher, G. P. Linette, J. Stec, E. Clark, M. Ayers, W. F. Symmans, L. Pusztai, and K. J. Bloom The HER-2/neu Gene and Protein in Breast Cancer 2003: Biomarker and Target of Therapy Oncologist, August 1, 2003; 8(4): 307 - 325. [Abstract] [Full Text] [PDF]

				S. De Placido, M. De Laurentiis, C. Carlomagno, C. Gallo, F. Perrone, S. Pepe, A. Ruggiero, A. Marinelli, C. Pagliarulo, L. Panico, et al. Twenty-year Results of the Naples GUN Randomized Trial: Predictive Factors of Adjuvant Tamoxifen Efficacy in Early Breast Cancer Clin. Cancer Res., March 1, 2003; 9(3): 1039 - 1046. [Abstract] [Full Text] [PDF]

				R. R. Love, N. B. Duc, T. C. Havighurst, S. K. Mohsin, Q. Zhang, D. L. DeMets, and D. C. Allred HER-2/neu Overexpression and Response to Oophorectomy Plus Tamoxifen Adjuvant Therapy in Estrogen Receptor-Positive Premenopausal Women With Operable Breast Cancer J. Clin. Oncol., February 1, 2003; 21(3): 453 - 457. [Abstract] [Full Text] [PDF]

				G. Konecny, G. Pauletti, M. Pegram, M. Untch, S. Dandekar, Z. Aguilar, C. Wilson, H.-M. Rong, I. Bauerfeind, M. Felber, et al. Quantitative Association Between HER-2/neu and Steroid Hormone Receptors in Hormone Receptor-Positive Primary Breast Cancer J Natl Cancer Inst, January 15, 2003; 95(2): 142 - 153. [Abstract] [Full Text] [PDF]

				M. F. Press, D. J. Slamon, K. J. Flom, J. Park, J.-Y. Zhou, and L. Bernstein Evaluation of HER-2/neu Gene Amplification and Overexpression: Comparison of Frequently Used Assay Methods in a Molecularly Characterized Cohort of Breast Cancer Specimens J. Clin. Oncol., July 15, 2002; 20(14): 3095 - 3105. [Abstract] [Full Text] [PDF]

				J. A. Zujewski "Build Quality in"--HER2 Testing in the Real World J Natl Cancer Inst, June 5, 2002; 94(11): 788 - 789. [Full Text] [PDF]

				C. Van Poznak, L. Tan, K. S. Panageas, C. D. Arroyo, C. Hudis, L. Norton, and A. D. Seidman Assessment of Molecular Markers of Clinical Sensitivity to Single-Agent Taxane Therapy for Metastatic Breast Cancer J. Clin. Oncol., May 1, 2002; 20(9): 2319 - 2326. [Abstract] [Full Text] [PDF]

				M. Colleoni, N. Rotmensz, C. Robertson, L. Orlando, G. Viale, G. Renne, A. Luini, P. Veronesi, M. Intra, R. Orecchia, et al. Very young women (<35 years) with operable breast cancer: features of disease at presentation Ann. Onc., February 20, 2002; 13(2): 273 - 279. [Abstract] [Full Text] [PDF]

				D. F. Hayes, H. Yamauchi, G. Broadwater, C. T. Cirrincione, S. P. Rodrigue, D. A. Berry, J. Younger, L. L. Panasci, F. Millard, D. B. Duggan, et al. Circulating HER-2/erbB-2/c-neu (HER-2) Extracellular Domain as a Prognostic Factor in Patients with Metastatic Breast Cancer: Cancer and Leukemia Group B Study 8662 Clin. Cancer Res., September 1, 2001; 7(9): 2703 - 2711. [Abstract] [Full Text] [PDF]

				R. Simon, A. Nocito, T. Hubscher, C. Bucher, J. Torhorst, P. Schraml, L. Bubendorf, M. M. Mihatsch, H. Moch, K. Wilber, et al. Patterns of HER-2/neu Amplification and Overexpression in Primary and Metastatic Breast Cancer J Natl Cancer Inst, August 1, 2001; 93(15): 1141 - 1146. [Abstract] [Full Text] [PDF]

				H. Yamauchi, V. Stearns, and D. F. Hayes When Is a Tumor Marker Ready for Prime Time? A Case Study of c-erbB-2 as a Predictive Factor in Breast Cancer J. Clin. Oncol., April 15, 2001; 19(8): 2334 - 2356. [Abstract] [Full Text] [PDF]

				B. K. Linderholm, T. Lindahl, L. Holmberg, S. Klaar, J. Lennerstrand, R. Henriksson, and J. Bergh The Expression of Vascular Endothelial Growth Factor Correlates with Mutant p53 and Poor Prognosis in Human Breast Cancer Cancer Res., March 1, 2001; 61(5): 2256 - 2260. [Abstract] [Full Text]

				S. Eppenberger-Castori, W. Kueng, C. Benz, R. Caduff, Z. Varga, F. Bannwart, D. Fink, H. Dieterich, M. Hohl, H. Muller, et al. Prognostic and Predictive Significance of ErbB-2 Breast Tumor Levels Measured by Enzyme Immunoassay J. Clin. Oncol., February 1, 2001; 19(3): 645 - 656. [Abstract] [Full Text] [PDF]

				M. Ferrero-Poüs, K. Hacène, C. Bouchet, V. Le Doussal, M. Tubiana-Hulin, and F. Spyratos Relationship between c-erbB-2 and Other Tumor Characteristics in Breast Cancer Prognosis Clin. Cancer Res., December 1, 2000; 6(12): 4745 - 4754. [Abstract] [Full Text]

				A. Pich, E. Margaria, and L. Chiusa Oncogenes and Male Breast Carcinoma: c-erbB-2 and p53 Coexpression Predicts a Poor Survival J. Clin. Oncol., August 16, 2000; 18(16): 2948 - 2956. [Abstract] [Full Text] [PDF]

				Y. Nieto, P. J. Cagnoni, S. Nawaz, E. J. Shpall, R. Yerushalmi, B. Cook, P. Russell, J. McDermit, J. Murphy, S. I. Bearman, et al. Evaluation of the Predictive Value of Her-2/neu Overexpression and p53 Mutations in High-Risk Primary Breast Cancer Patients Treated With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation J. Clin. Oncol., May 10, 2000; 18(10): 2070 - 2080. [Abstract] [Full Text] [PDF]

				R. Gorlick, A. G. Huvos, G. Heller, A. Aledo, G. P. Beardsley, J. H. Healey, and P. A. Meyers Expression of HER2/erbB-2 Correlates With Survival in Osteosarcoma J. Clin. Oncol., September 1, 1999; 17(9): 2781 - 2781. [Abstract] [Full Text] [PDF]

				T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes, and S. J. Schnitt Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of HER-2/neu in Breast Cancer J. Clin. Oncol., July 1, 1999; 17(7): 1974 - 1974. [Abstract] [Full Text] [PDF]

				T. W. Jacobs, A. M. Gown, H. Yaziji, M. J. Barnes, and S. J. Schnitt Specificity of HercepTest in Determining HER-2/neu Status of Breast Cancers Using the United States Food and Drug Administration-Approved Scoring System J. Clin. Oncol., July 1, 1999; 17(7): 1983 - 1983. [Abstract] [Full Text] [PDF]

				A. Scorilas, J. Yotis, C. Pateras, T. Trangas, and M. Talieri Predictive Value of c-erbB-2 and Cathepsin-D for Greek Breast Cancer Patients Using Univariate and Multivariate Analysis Clin. Cancer Res., April 1, 1999; 5(4): 815 - 821. [Abstract] [Full Text] [PDF]